Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

MLA

Thomalla, D., et al. “Deregulation and Epigenetic Modification of BCL2-Family Genes Cause Resistance to Venetoclax in Hematologic Malignancies.” Blood, vol. 140, no. 20, Nov. 2022, pp. 2113–26. EBSCOhost, https://doi.org/10.1182/blood.2021014304.

APA

Thomalla, D., Beckmann, L., Grimm, C., Oliverio, M., Meder, L., Herling, C. D., Nieper, P., Feldmann, T., Merkel, O., Lorsy, E., da Palma Guerreiro, A., von Jan, J., Kisis, I., Wasserburger, E., Claasen, J., Faitschuk-Meyer, E., Altmüller, J., Nürnberg, P., Yang, T.-P., … Frenzel, L. P. (2022). Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood, 140(20), 2113–2126. https://doi.org/10.1182/blood.2021014304

Chicago

Thomalla, D., L. Beckmann, C. Grimm, M. Oliverio, L. Meder, C. D. Herling, P. Nieper, et al. 2022. “Deregulation and Epigenetic Modification of BCL2-Family Genes Cause Resistance to Venetoclax in Hematologic Malignancies.” Blood 140 (20): 2113–26. doi:10.1182/blood.2021014304.